Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2784-2789

  Conley, Sarah J ^a   Gheordunescu, Elizabeth ^a   Kakarala, Pramod ^a   Newman, Bryan ^a   Korkaya, Hasan ^a   Heath, Amber N ^a   Clouthier, Shawn G ^a   Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Antiangiogenesis; HIF 1

Indexed keywords

BETA CATENIN; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR HYPOXIA; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL COUNT; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; MICE; NEOPLASTIC STEM CELLS; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84857407549     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018866109     Document Type: Article

References (38)

1. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
2. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
3. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603.
4. Burstein HJ, et al. (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816.
5. Johannsen M, et al. (2009) Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55:1430-1438.
6. Ebos JM, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.
7. Pàez-Ribes M, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231.
8. Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clin Cancer Res 16:5928-5935.
9. Soeda A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α. Oncogene 28:3949-3959.
10. Seidel S, et al. (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 α. Brain 133:983-995.
11. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274-3284.
12. Charafe-Jauffret E, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302-1313.
13. Christensen JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18 (Suppl 10):x3-x10.
14. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104:17069-17074. (Pubitemid 350210993)
15. Ginestier C, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567. (Pubitemid 350056407)
16. Haznedar JO, et al. (2009) Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 64:691-706.
17. Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335-345. (Pubitemid 40767935)
18. Korkaya H, et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. PLoS Biol 7:e1000121.
19. Liu L, et al. (2010) Activation of β-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16:2740-2750.
20. 2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol 12:1007-1013.
21. Méndez O, et al. (2010) Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 9:133.
22. Xu K, et al. (2010) Silencing of HIF-1α suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther 17:212-222.
23. Choi H, Chun YS, Kim TY, Park JW (2010) HIF-2α enhances β-catenin/TCF-driven transcription by interacting with β-catenin. Cancer Res 70:10101-10111.
24. Kaidi A, Williams AC, Paraskeva C (2007) Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9:210-217. (Pubitemid 46420864)
25. Bouras T, et al. (2008) Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3:429-441.
26. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
27. Kong D, et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5:e12445.
28. Yang MH, et al. (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12:982-992.
29. Cannito S, et al. (2010) Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal 12:1383-1430.
30. Folkins C, et al. (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560-3564. (Pubitemid 46762138)
31. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104:5431-5436. (Pubitemid 47175697)
32. 2 distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 81:685-696.
33. 2 distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J 81:675-684.
34. Hambardzumyan D, Becher OJ, Holland EC (2008) Cancer stem cells and survival pathways. Cell Cycle 7:1371-1378. (Pubitemid 351872575)
35. Christensen K, Schrøder HD, Kristensen BW (2008) CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 90(2):157-170.
36. Gilbertson RJ, Rich JN (2007) Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733-736. (Pubitemid 47463683)
37. Krishnamurthy S, et al. (2010) Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 70:9969-9978.
38. Hayes DF (2011) Bevacizumab treatment for solid tumors: Boon or bust? JAMA 305:506-508.